Myeloma cells suppress osteoblasts through sclerostin secretion. - Wikidata - wikimedia - TriplyDB

Myeloma cells suppress osteoblasts through sclerostin secretion.

Myeloma cells suppress osteoblasts through sclerostin secretion.

http://www.wikidata.org/entity/Q38323256

about

Role of osteocytes in multiple myeloma bone disease Management of endocrine disease: Secondary osteoporosis: pathophysiology and management Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate.Novel therapeutic targets in myeloma bone disease.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics A review of osteocyte function and the emerging importance of sclerostin unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease.Bone-immune cell crosstalk: bone diseases.Bone anabolic agents for the treatment of multiple myeloma.Targeting bone as a therapy for myeloma.Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast Effects of Combined Exposure to Lead and High-Fat Diet on Bone Quality in Juvenile Male Mice Osteogenic differentiation of dental follicle stem cells.Multiple myeloma in the marrow: pathogenesis and treatments.Cellular mechanisms of multiple myeloma bone disease The Interplay between the bone and the immune system Effects of proteasome inhibitors on bone cancer Serum sclerostin levels in renal cell carcinoma patients with bone metastases Signaling between tumor cells and the host bone marrow microenvironment.Human myeloma cell lines induce osteoblast downregulation of CD99 which is involved in osteoblast formation and activity.Myeloma and Bone Disease.Mechanisms of osteolytic and osteoblastic skeletal lesions.Molecular mechanisms, current management and next generation therapy in myeloma bone disease.Role and mechanism of action of sclerostin in bone.Hormonal and systemic regulation of sclerostin.Emerging treatment approaches for myeloma-related bone disease.An Evidence-Based Approach to Myeloma Bone Disease.WNT signalling events near the cell membrane and their pharmacological targeting for the treatment of cancer.Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer.Osteogenic inhibition in multiple myeloma.Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.Immunology of Gut-Bone Signaling.Monoclonal antibodies for treating osteoporosis.Pathogenesis of bone disease in multiple myeloma: from bench to bedside.Mechanisms of bone destruction in multiple myeloma.Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.Bone-Targeted Therapies in Cancer-Induced Bone Disease.Bone Disease in Multiple Myeloma.

P2860

Q26992195-71AE2740-244A-4C44-AA67-93AA0FA7298D Q26998249-12EC431C-012D-4856-921A-62D114F73325 Q33695185-5F168994-6CCA-46EB-8204-434EA42E0473 Q34025065-7FAAE902-5089-4BD7-B0E0-EC4F4BB29AB6 Q34038854-12AE216A-4F20-4D3C-8A6A-59A3BF19BD07 Q34264395-B260136F-B129-4560-BB45-8C38AC055028 Q34718186-9D9F9241-6FE7-4331-A633-A5206D811052 Q35149611-499E6C16-5BA8-45BE-A685-2952A1AC6F2A Q35592362-A294B150-AAA6-476A-BA9F-579BF30F8ED2 Q35603116-E5E27399-AEFC-46EE-859C-55C886E0E72A Q35603128-95317C4E-35ED-4A7D-912C-2C5766DB6EDC Q36086488-29AF6007-6CA6-48CF-8C55-18AEABB2F2E4 Q36112026-F4C30D66-0A44-4D7B-87CB-42D4757C6B29 Q36190191-EE69E797-87AC-4CB9-AA92-4BF1FE417361 Q36725401-198C2A70-E9D0-4D28-9238-98E8FF14CA6C Q36925346-31C30D93-A83C-4803-821B-3A6C12120400 Q37052226-BA110B24-9C45-44CB-BB64-91B03E49C75A Q37281071-F0227E27-496A-48A3-8B22-05717C42CFA3 Q37282121-A41A23FE-0ED0-4CDE-A397-07A0DC817C3B Q38138849-EB40CDE9-FAF3-46D7-B49E-BBE1BA66865C Q38298890-C97F0E1A-B639-4175-8016-53F178435B47 Q38598342-ED4B7B02-0E67-4FC1-98B3-6D1BED612DF4 Q38625793-46294A42-10FB-4200-A334-6A8B6B54A6C2 Q38749233-1A6875C4-747D-4E24-A54F-E8902AA3A6E0 Q38807230-8481C0D7-706E-4113-ADB4-AE4061082488 Q39037907-F5FA185B-C29C-4FC7-A5CE-F63BF594055F Q39090721-C12A5A71-9597-4F81-ACE9-5446ECA38C4F Q39153978-616A680A-6A35-470C-B9F5-BF400F5CC7FA Q39154095-7C41E289-9236-42BD-9687-A83D55E39F4B Q40111192-8810022A-F026-4DC1-B70F-932029BF9257 Q41194152-BCF7584B-8E4F-45D9-8267-D21CD8492062 Q42597494-4BC832A2-7CE7-4BEB-87F4-56867A31210B Q43965394-20D6894A-1259-41CA-AF6F-C8E7B233DF0D Q47100950-91ED4C0E-0712-4149-9A4B-B38BE3A4E645 Q47638169-965268D6-71BD-4B94-AF88-B18164ADB2B3 Q47734632-71BBE4D0-DE58-40D3-B463-E0E0EDC3D26B Q47756922-48A61819-4006-46F8-81FF-780C9FDB65BB Q47909734-A6705A9E-174D-48D3-AF3E-20EFEF1826FD Q48110513-E65F7E71-330A-4C61-976F-45EC5C17417D Q50888455-17342DCD-E004-4C18-B077-071A7F134A9F

P2860

Myeloma cells suppress osteoblasts through sclerostin secretion.

http://www.wikidata.org/entity/Q38323256

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Myeloma cells suppress osteoblasts through sclerostin secretion.

@en

type

label

Myeloma cells suppress osteoblasts through sclerostin secretion.

@en

prefLabel

Myeloma cells suppress osteoblasts through sclerostin secretion.

@en

P1433

Q38323256-43E464DF-F8BB-4A7D-B172-4812445D67C6

P1476

Q38323256-C9A5AA3A-5864-40BE-ABA9-8F80DF0DD8EA

P2093

Q38323256-153C139E-2F63-47C0-8859-F222E475CB24

Q38323256-19BA4B41-86F2-4D22-ADA4-40BB6BB7C2CA

Q38323256-45CAC2AB-CF98-485A-A808-380F39C8896C

Q38323256-85198E45-D461-4096-9959-71FEE37DC16D

Q38323256-8F6A0C45-00BF-40EE-ABBE-A61E04935E88

Q38323256-BE583A2F-4096-4532-98CB-1F66056FC93A

Q38323256-F9CAA561-77F3-4E49-9B3F-6471D2BD0C46

P2860

Q38323256-008D249A-0C70-4A5A-B78E-56EB931C211C

Q38323256-065E8E44-477A-48E1-89D7-79F8C96BF08B

Q38323256-15F86C29-F050-445C-8614-CBBDD5159218

Q38323256-1D44AB91-BA41-420C-8612-165C01E67AA1

Q38323256-1D4A0216-F3FF-4F3A-A272-E059A0BFF42E

Q38323256-222DB350-981B-4409-9A1B-B53F1318449A

Q38323256-2A296E8F-6473-41E2-B34C-720C68DF0854

Q38323256-2C00C3FE-CD43-44DA-8CBC-CD7481E0B792

Q38323256-2CCCE462-9835-4DBA-8D21-CDCC51B8FFF6

Q38323256-2D89B41A-EDAF-40DF-8A4D-7EE77A6608E6

P2888

Q38323256-9C237530-1F79-419E-B108-61AE6CCC5D44

P304

Q38323256-372C8376-F72A-4212-A505-CFE1DC4F82C5

P31

Q38323256-3365CB47-A6D9-46BC-B89D-B451DA039CDD

P356

Q38323256-E58190FD-333C-4492-B827-0947BB1A9A61

P433

Q38323256-E2E4CA75-B5AF-4923-A4D0-BDFFECE7AF25

P478

Q38323256-64906406-201A-4358-B6E1-B40783E87693

P50

Q38323256-2F4E8F2C-153D-4A5F-90A8-F058C920449D

Q38323256-382CB770-19E5-4BA7-B0CF-E259C1F983B9

Q38323256-7AC45DC2-D974-449C-9D0D-1597A38ACC53

Q38323256-9D593141-8625-49B1-A348-1CC9B63C5ED2

Q38323256-DD6D7089-A4D3-42E6-A7E8-72288061B220

Q38323256-EEA8ABC1-13F9-4854-AF5F-01B02D699141

P577

Q38323256-82FB0A65-03CD-43D9-8685-186478A8DAEA

P5875

Q38323256-9B1D9FE5-B6D6-4DDF-ACB4-715B224289C0

P6179

Q38323256-36C3348A-DE01-43DB-8112-95F6209EC910

P698

Q38323256-5D2AA4F8-8A03-4C53-BCEB-5931DA56F4BE

P921

Q38323256-44517AED-1284-45A2-84EB-0F46CBB5FA1B

P932

Q38323256-E6B88EC0-52ED-41E4-9499-5203DE4B286C

P356

P1433

Blood Cancer Journal

P1476

Myeloma cells suppress osteoblasts through sclerostin secretion.

@en

P2093

A Oranger

http://www.w3.org/2001/XMLSchema#string

A Zallone

http://www.w3.org/2001/XMLSchema#string

E Rinaldi

http://www.w3.org/2001/XMLSchema#string

F Sardone

http://www.w3.org/2001/XMLSchema#string

G Passeri

http://www.w3.org/2001/XMLSchema#string

P Curci

http://www.w3.org/2001/XMLSchema#string

V Liso

http://www.w3.org/2001/XMLSchema#string

P2860

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

P2888

P304

e27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BCJ.2011.22

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Giorgina Specchia

Giacomina Brunetti

P577

2011-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230565442

http://www.w3.org/2001/XMLSchema#string

P6179

1003987311

http://www.w3.org/2001/XMLSchema#string

P698

22829171

http://www.w3.org/2001/XMLSchema#string

P921

P932

3255263

http://www.w3.org/2001/XMLSchema#string